Prophylaxis against carcinogenesis in three kinds of unestablished tumor models via IL12-gene-engineered MSCs

作者：Xin Chen, Ruojun Wang, X. Zhao, Yuquan Wei, Mengyun Hu, Y.-s. Wang, X.-w. Zhang, R. Zhang, Li Zhang, Bin Yao, L. Wang, Yuefeng Jia, Tingting Zeng, Jinsun Yang, Li Tian, B. Kan, Xiaojuan Lin, S. Lei, Huan Deng, Yue Wen, YanJie Mao, Jianbin Li · 发表于：Carcinogenesis · 年份：2006 · DOI：10.1093/carcin/bgl069 · 被引用次数：80 · 研究领域：Virus-based gene therapy research、CAR-T cell therapy research、Mesenchymal stem cell research

Mesenchymal stem cells (MSCs) were adenovirally engineered to secrete interleukin-12 (AdIL-12-MSCs) and evaluated for their anticarcinogenesis efficacy against three kinds of unestablished tumor models including B16 melanoma, LLC Lewis lung cancer and HCC hepatoma. Injection of AdIL-12-MSCs into protected mice before tumor inoculation prevented all of 12 mice in B16 preventive groups, 10 out of 12 in LLC lung cancer model and 11 out of 12 mice in HCC hepatoma model from developing tumors, whereas the control groups pre-receiving PBS were validated for 100% carcinogenesis; the tumor formation rates in free-AdIL-12 and vacant MSC groups were unveiled between approximately 83 and 100% even with plentiful angiogenesis and newborn lymphatic vessels, as well as distant metastases. As a novel approach, AdIL-12-MSC has revealed expected preventive effects on carcinogenesis (P<0.01) with low-toxic, broad-spectrum and long-range superiorities. In conclusion, our data indicate that AdIL-12-MSC possess the potential for tropism to preclinical tumor lesions and deprives surviving or hibernating tumor cells, which have escaped from conventional treatments, of revival and recurrence.